All Publications

Data provided by UCSF Profiles, powered by CTSI at UCSF
  1. Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023 Sep 07. View in PubMed
  2. Wu X, Kwong A, Heller M, Lokken RP, Fidelman N, Mehta N. Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant. Liver Transpl. 2023 Aug 29. View in PubMed
  3. Wang M, Cedars MI, Mehta N, Sarkar M. How I Approach Hepatocellular Adenomas in Hormonally Distinct Populations: Time to Think Outside the (Contraceptive Pill) Box. Am J Gastroenterol. 2023 Oct 02. View in PubMed
  4. Yilma M, Mehta N. Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2024 Jan; 33(1):133-142. View in PubMed
  5. Ivanics T, Claasen MP, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Quintini C, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ. Living Donor Liver Transplantation (LDLT) for Hepatocellular Carcinoma (HCC) within and Outside Traditional Selection Criteria: A Multicentric North American Experience. Ann Surg. 2023 Jul 31. View in PubMed
  6. Natarajan B, Tabrizian P, Hoteit M, Frenette C, Parikh N, Ghaziani T, Dhanasekaran R, Guy J, Shui A, Florman S, Yao FY, Mehta N. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium. Am J Transplant. 2023 11; 23(11):1771-1780. View in PubMed
  7. Yilma M, Cogan R, Shui AM, Neuhaus JM, Light C, Braun H, Mehta N, Hirose R. Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome. Hepatol Commun. 2023 07 01; 7(7). View in PubMed
  8. Norman J, Mehta N, Kwong A. Optimizing liver transplant prioritization for hepatocellular carcinoma through risk stratification. Curr Opin Organ Transplant. 2023 Aug 01; 28(4):265-270. View in PubMed
  9. Yilma M, Kim NJ, Shui AM, Tana M, Landis C, Chen A, Bangaru S, Mehta N, Zhou K. Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals. JAMA Netw Open. 2023 Jun 01; 6(6):e2317549. View in PubMed
  10. Yilma M, Dalal N, Wadhwani SI, Hirose R, Mehta N. Geographic disparities in access to liver transplantation. Liver Transpl. 2023 09 01; 29(9):987-997. View in PubMed
  11. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023 May 22. View in PubMed
  12. Mehta N, Kelley RK, Yao FY. Refining the approach to down-staging for hepatocellular carcinoma prior to liver transplantation: Patient selection, local-regional treatments, and systemic therapies. Hepatology. 2023 May 16. View in PubMed
  13. Mehta N, Kotwani P, Norman J, Shui A, Li PJ, Saxena V, Chan W, Yao FY. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study. Liver Transpl. 2023 10 01; 29(10):1041-1049. View in PubMed
  14. Wu X, Lokken RP, Mehta N. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy? JHEP Rep. 2023 Aug; 5(8):100781. View in PubMed
  15. Hoffman D, Shui A, Gill R, Syed S, Mehta N. Resected Tumor Outcome and Recurrence (RESTORE) Index for Hepatocellular Carcinoma Recurrence after Resection. Cancers (Basel). 2023 Apr 24; 15(9). View in PubMed
  16. Rice BA, Mehta N, Grab J, Dodge JL, Sherman CB. Patient survey augments detection of harmful alcohol relapse after liver transplant for alcohol-associated cirrhosis. Hepatol Commun. 2023 05 01; 7(5). View in PubMed
  17. Singal AG, Ghaziani TT, Mehta N, Zhou K, Grinspan LT, Benhammou JN, Moon AM, Yang JD, Salgia R, Pillai A, Zheng E, Rich NE, Gopal P, Jalal P, Verna E, Yekkaluri S, Phen S, Melendez-Torres J, Alshuwaykh O, Choi H, Junus K, Grady J, Song M, Leven EA, Yum J, Gowda V, Alsudaney M, Hernandez P, Desai N, Parikh ND. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3). View in PubMed
  18. X. Wu, A. Kwong, M. Heller, R. Lokken, N. Fidelman, N. Mehta. Abstract No. 251 ? FEATURED ABSTRACT Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for Downstaging of Hepatocellular Carcinoma Before Liver Transplant. Journal of Vascular and Interventional Radiology. 2023 Mar 1; 34(3):s114. View in PubMed
  19. Wu X, Heller M, Kwong A, Fidelman N, Mehta N. Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates. J Vasc Interv Radiol. 2023 07; 34(7):1237-1246.e3. View in PubMed
  20. Ivanics T, Claasen MPAW, Patel MS, Giorgakis E, Khorsandi SE, Srinivasan P, Prachalias A, Menon K, Jassem W, Cortes M, Sayed BA, Mathur AK, Walker K, Taylor R, Heaton N, Mehta N, Segev DL, Massie AB, van der Meulen JHP, Sapisochin G, Wallace D. Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US. Liver Int. 2023 05; 43(5):1107-1119. View in PubMed
  21. Brown AE, Shui AM, Adelmann D, Mehta N, Roll GR, Hirose R, Syed SM. Number of Local Regional Therapies for Hepatocellular Carcinoma and Peri-Operative Outcomes after Liver Transplantation. Cancers (Basel). 2023 Jan 19; 15(3). View in PubMed
  22. Qureshy Z, Lokken RP, Kakar S, Grab J, Mehta N, Sarkar M. Influence of progestin-only hormonal use on hepatocellular adenomas: A retrospective cohort study. Contraception. 2023 03; 119:109915. View in PubMed
  23. Wong RJ, Jayasekera C, Jones P, Kanwal F, Singal AG, Ahmed A, Taglienti R, Younossi Z, Kulik L, Mehta N. An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma. Gastroenterology Res. 2022 Dec; 15(6):297-307. View in PubMed
  24. Wang M, Sarkar M, Mehta N. Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression. Hepatology. 2023 02 01; 77(2):341-343. View in PubMed
  25. Ivanics T, Wallace D, Claasen MPAW, Patel MS, Brahmbhatt R, Shwaartz C, Prachalias A, Srinivasan P, Jassem W, Heaton N, Cattral MS, Selzner N, Ghanekar A, Morgenshtern G, Mehta N, Massie AB, van der Meulen J, Segev DL, Sapisochin G. Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada. J Hepatol. 2022 12; 77(6):1607-1618. View in PubMed
  26. Huang AC, Dodge JL, Yao FY, Mehta N. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol. 2023 06; 21(6):1581-1589. View in PubMed
  27. Kwong AJ, Mehta N. Liver allocation policies for hepatocellular carcinoma have leveled the playing field-But who should be playing? Liver Transpl. 2022 12; 28(12):1821-1822. View in PubMed
  28. Bernards S, Lee E, Leung N, Akan M, Gan K, Zhao H, Sarkar M, Tayur S, Mehta N. Awarding additional MELD points to the shortest waitlist candidates improves sex disparity in access to liver transplant in the United States. Am J Transplant. 2022 Dec; 22(12):2912-2920. View in PubMed
  29. Giard JM, Dodge JL, Yao FY, Mehta N. Liver Transpl. 2022 Jul 21; 233-235. View in PubMed
  30. Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, Busuttil RW, Roberts J, Emond JC, Samstein B, Brown RS, Najjar M, Chapman WC, Doyle MM, Florman SS, Schwartz ME, Llovet JM. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma. JAMA Surg. 2022 09 01; 157(9):779-788. View in PubMed
  31. Giard JM, Dodge JL, Yao FY, Mehta N. Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation. Liver Transpl. 2023 02 01; 29(2):233-235. View in PubMed
  32. Parikh ND, Mehta N, Hoteit MA, Yang JD, John BV, Moon AM, Salgia RJ, Pillai A, Kassab I, Saeed N, Thyssen E, Nathani P, McKinney J, Chan W, Durkin C, Connor M, Alsudaney M, Konjeti R, Durand B, Nissen NN, Kim HP, Paknikar R, Rich NE, Schipper MJ, Singal AG. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478. View in PubMed
  33. X. Wu, M. Heller, A. Kwong, N. Fidelman, N. Mehta. Abstract No. 261 Cost-effectiveness analysis of interventional liver-directed therapies for a single, small (< 3 cm) hepatocellular carcinoma in liver transplant candidates. Journal of Vascular and Interventional Radiology. 2022 Jun 1; 33(6):s120. View in PubMed
  34. Chen AK, Lunow-Luke T, Yamaguchi S, Praglin C, Agudelo E, Mehta N, Dirks R, Braun HJ, Gardner JM, Roberts JP, Syed SM, Roll GR. Nodular Regenerative Hyperplasia After Liver Transplant; It's All in the Presentation. Front Surg. 2022; 9:876818. View in PubMed
  35. Varun Saxena, Liyan Liu, Joanna B. Ready, Mai Sedki, Krisna P. Chai, Suk I. Seo, Nizar A. Mukhtar, Sreepriya Balasubramanian, Brock A. Macdonald, Neil Mehta, Julie A. Schmittdiel. 531: DEVELOPMENT AND VALIDATION OF A RISK SCORE FOR PREDICTING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B WITHIN A LARGE, REPRESENTATIVE, NORTHERN CALIFORNIA COHORT. Gastroenterology. 2022 May 1; 162(7):s-1131. View in PubMed
  36. Mignote Yilma, Jackson Voelkel, Richie Houhong Xu, Leu-Yen Tucker, Monica Muzzin, Varun Saxena, Neil Mehta, Jeffrey K. Lee, Suk I. Seo, Brock A. Macdonald, Joanna B. Ready, Sreepriya Balasubramanian, Nizar A. Mukhtar. EP1003: EVALUATION OF SOCIOECONOMIC STATUS WITHIN HOTSPOTS OF HEPATOCELLULAR CARCINOMA AMONG A LARGE DIVERSE PATIENT COHORT IN NORTHERN CALIFORNIA. Gastroenterology. 2022 May 1; 162(7):s-1277. View in PubMed
  37. Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N. National experience with living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2022 07; 28(7):1144-1157. View in PubMed
  38. Yilma M, Saxena V, Mehta N. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep. 2022 Jan; 24(1):1-9. View in PubMed
  39. Kwong A, Hameed B, Syed S, Ho R, Mard H, Arshad S, Ho I, Suleman T, Yao F, Mehta N. Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma. Cancer Med. 2022 03; 11(6):1535-1541. View in PubMed
  40. Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma. Liver Transpl. 2022 05; 28(5):763-773. View in PubMed
  41. Kwong AJ, Ghaziani TT, Mehta N. Decreased Urgency Among Liver Transplantation Candidates With Hepatocellular Carcinoma in the United States. Liver Transpl. 2022 04; 28(4):725-727. View in PubMed
  42. Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 05; 75(5):1289-1299. View in PubMed
  43. Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma. Liver Transpl. 2022 03; 28(3):376-385. View in PubMed
  44. Ivanics T, Wallace D, Abreu P, Claasen MPAW, Callaghan C, Cowling T, Walker K, Heaton N, Mehta N, Sapisochin G, van der Meulen J. Survival After Liver Transplantation: An International Comparison Between the United States and the United Kingdom in the Years 2008-2016. Transplantation. 2022 07 01; 106(7):1390-1400. View in PubMed
  45. Wallace D, Cowling TE, Suddle A, Gimson A, Rowe I, Callaghan C, Sapisochin G, Ivanics T, Claasen M, Mehta N, Heaton N, van der Meulen J, Walker K. National time trends in mortality and graft survival following liver transplantation from circulatory death or brainstem death donors. Br J Surg. 2021 12 17; 109(1):79-88. View in PubMed
  46. Reddy SHS, Mehta N, Dodge JL, Hakeem AR, Khorsandi SE, Jassem W, Vilca-Melendez H, Cortes-Cerisuelo M, Srinivasan P, Prachalias A, Heneghan MA, Aluvihare V, Suddle A, Miquel R, Rela M, Heaton ND, Menon KV. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort. HPB (Oxford). 2022 05; 24(5):596-605. View in PubMed
  47. Mehta N, Yao FY. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolization: Pipe Dream or Reality? Liver Transpl. 2021 12; 27(12):1706-1708. View in PubMed
  48. Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2022 05; 20(5):1142-1150.e4. View in PubMed
  49. Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021 11; 161(5):1502-1512. View in PubMed
  50. Mehta N. Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management. Clin Liver Dis (Hoboken). 2021 May; 17(5):332-336. View in PubMed
  51. Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg. 2021 06 01; 156(6):559-567. View in PubMed
  52. Neehar D. Parikh, Neil Mehta, Maarouf Hoteit, Ju Dong Yang, Binu V. John, Andrew M. Moon, Reena Salgia, Anjana A. Pillai, Ihab Kassab, Naba Saeed, Emil Thyssen, Piyush Nithani, Jeffrey Mckinney, Wesley Chan, Claire Durkin, Matthew Connor, Manaf Alsudaney, Brenda Durand, Nicholas N. Nissen, Hannah P. Kim, Raghavendra Paknikar, Nicole E. Rich, Matthew Schipper, Amit G. Singal. 433 THE ASSOCIATION OF SUSTAINED VIROLOGIC RESPONSE ON TREATMENT OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA WITH HEPATITIS C. Gastroenterology. 2021 May 1; 160(6):s-776. View in PubMed
  53. Neil Mehta. Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management. Clinical Liver Disease. 2021 May 1; 17(5):332-336. View in PubMed
  54. Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol. 2021 05; 216(5):1283-1290. View in PubMed
  55. Harding-Theobald E, Yao FYK, Mehta N. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl. 2021 06; 27(6):818-829. View in PubMed
  56. Kotwani P, Chan W, Yao F, Mehta N. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study. Clin Gastroenterol Hepatol. 2022 03; 20(3):701-703.e2. View in PubMed
  57. Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis. 2021 05; 41(2):117-127. View in PubMed
  58. Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. Sex-based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation. 2021 11 01; 105(11):2420-2426. View in PubMed
  59. Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2022 02; 20(2):409-418.e5. View in PubMed
  60. Braun HJ, Schwab MP, Jin C, Amara D, Mehta NJ, Grace TR, Croci R, Freise CE, Roberts JP, Hirose R, Ascher NL. Opioid use prior to liver transplant is associated with increased risk of death after transplant. Am J Surg. 2021 07; 222(1):234-240. View in PubMed
  61. Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol. 2021 04; 74(4):829-837. View in PubMed
  62. Varun Saxena, Neil Mehta. Current Transplant Criteria for Hepatocellular Carcinoma—Overuse or Underuse. Current Hepatology Reports. 2020 Nov 4; 1-8. View in PubMed
  63. Younis J, Freitag H, Ruthberg JS, Romanes JP, Nielsen C, Mehta N. Social Media as an Early Proxy for Social Distancing Indicated by the COVID-19 Reproduction Number: Observational Study. JMIR Public Health Surveill. 2020 10 20; 6(4):e21340. View in PubMed
  64. Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis. 2021 02; 25(1):19-33. View in PubMed
  65. Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol. 2021 Jan; 15(1):91-102. View in PubMed
  66. Weinfurtner K, Dodge JL, Yao FYK, Mehta N. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. Transplant Direct. 2020 Oct; 6(10):e605. View in PubMed
  67. Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193. View in PubMed
  68. Zhou K, Mehta N. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis. 2020 11; 24(4):665-679. View in PubMed
  69. Hillary Braun, Marisa P. Schwab, Chengshi Jin, Dominic Amara, Trevor Grace, Rhiannon Croci, Chris E. Freise, John P. Roberts, Neil Mehta, Ryutaro Hirose, Nancy L. Ascher. OPIOID USE PRIOR TO LIVER TRANSPLANT IS ASSOCIATED WITH INCREASED RISK OF DEATH AFTER TRANSPLANT. Transplantation. 2020 Sep 1; 104(S3):s489-s489. View in PubMed
  70. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 09 01; 5(9):1020-1026. View in PubMed
  71. Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci. 2020 12; 65(12):3456-3462. View in PubMed
  72. Kalra A, Hawkins ES, Nowacki AS, Jain V, Milinovich A, Saef J, Thomas G, Gebreselassie SK, Karnik SS, Jehi L, Young JB, Svensson LG, Chung MK, Mehta N. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19. Circ Cardiovasc Qual Outcomes. 2020 10; 13(10):e007115. View in PubMed
  73. Chung MK, Karnik S, Saef J, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB, Mehta N, Cameron SJ, McCrae KR, Schmaier AH, Smith JD, Kalra A, Gebreselassie SK, Thomas G, Hawkins ES, Svensson LG. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine. 2020 Aug; 58:102907. View in PubMed
  74. George Therapondos, Brian Lee, Gene Im, John Rice, Ann Lazar, Michael R. Lucey, Ethan Weinberg, Hyosun Han, Haripriya Maddur, R. Mark Ghobrial, Christine Hsu, Oren Fix, Sheila Eswaran, Kirti Shetty, Neha Jakhete, David Victor, David Foley, Neil Mehta, Mary Rinella, Thomas Schiano, Constance Mobley, Norah Terrault. THU248 Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage. Journal of Hepatology. 2020 Aug 1; 73:s262-s263. View in PubMed
  75. Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2021 08; 19(8):1520-1530. View in PubMed
  76. Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020 07 01; 3(7):e2014780. View in PubMed
  77. Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions. Transplantation. 2020 11; 104(11):2215-2220. View in PubMed
  78. Mehta N, Yao FY. Reply. Hepatology. 2020 12; 72(6):2243-2244. View in PubMed
  79. Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl. 2020 09; 26(9):1100-1111. View in PubMed
  80. Poplawski GHD, Kawaguchi R, Van Niekerk E, Lu P, Mehta N, Canete P, Lie R, Dragatsis I, Meves JM, Zheng B, Coppola G, Tuszynski MH. Injured adult neurons regress to an embryonic transcriptional growth state. Nature. 2020 05; 581(7806):77-82. View in PubMed
  81. Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020 06; 104(6):1136-1142. View in PubMed
  82. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology. 2020 11; 72(5):1654-1665. View in PubMed
  83. Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int. 2020 05; 33(5):567-575. View in PubMed
  84. Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun. 2020 Mar; 4(3):342-354. View in PubMed
  85. Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation. 2020 10; 104(10):2087-2096. View in PubMed
  86. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival. Transplantation. 2020 10; 104(10):2105-2112. View in PubMed
  87. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change. Liver Transpl. 2020 05; 26(5):662-672. View in PubMed
  88. Cullaro G, Rubin JB, Mehta N, Lai JC. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Liver Transpl. 2020 03; 26(3):349-358. View in PubMed
  89. Lee E, Sarkar M, Dodge J, Kohi M, Mehta N. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma. Transplantation. 2020 05; 104(5):988-995. View in PubMed
  90. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 08 02; 2(8):e1910326. View in PubMed
  91. Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study. Prehosp Disaster Med. 2019 Aug; 34(4):393-400. View in PubMed
  92. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2. View in PubMed
  93. Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983. View in PubMed
  94. Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology. 2020 03; 71(3):943-954. View in PubMed
  95. Mehta N, Dodge JL, Yao FY. REPLY. Hepatology. 2019 10; 70(4):1491-1492. View in PubMed
  96. Brian Lee, Mary Rinella, Gene Im, John Rice, Oren Fix, George Therapondos, Hyosun Han, David Victor, Ethan Weinberg, Cristine Hsu, Michael Voigt, Haripriya Maddur, Sheila Eswaran, David Foley, R. Mark Ghobrial, Lisanne Dinges, Jennifer Dodge, Neil Mehta, Michael R. Lucey, Norah Terrault. PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis. Journal of Hepatology. 2019 Apr 1; 70(1):e137. View in PubMed
  97. Brian Lee, Mary Rinella, Gene Im, John Rice, Oren Fix, George Therapondos, Hyosun Han, David Victor, Ethan Weinberg, Cristine Hsu, Michael Voigt, Haripriya Maddur, Sheila Eswaran, David Foley, R. Mark Ghobrial, Lisanne Dinges, Jennifer Dodge, Neil Mehta, Michael R. Lucey, Norah Terrault. PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis. . 2019 Apr 1; 70(1):e137. View in PubMed
  98. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 08; 19(8):2210-2218. View in PubMed
  99. Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25. View in PubMed
  100. Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 10; 70(4):1185-1196. View in PubMed
  101. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1. View in PubMed
  102. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 03; 69(3):1193-1205. View in PubMed
  103. Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217. View in PubMed
  104. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2019 06; 21(6):731-738. View in PubMed
  105. Subramanian A, Connor DM, Berger G, Lessing JN, Mehta N, Manesh R, Kohlwes J. A Curriculum for Diagnostic Reasoning: JGIM's Exercises in Clinical Reasoning. J Gen Intern Med. 2019 03; 34(3):344-345. View in PubMed
  106. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 10; 24(10):1346-1356. View in PubMed
  107. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 02; 25(2):207-216. View in PubMed
  108. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 02; 25(2):228-241. View in PubMed
  109. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl. 2018 09; 24(9):1171-1177. View in PubMed
  110. Roberts DE, Kakar S, Mehta N, Gill RM. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence. Am J Surg Pathol. 2018 07; 42(7):855-865. View in PubMed
  111. Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes. Transplant Direct. 2018 Jul; 4(7):e363. View in PubMed
  112. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018 08; 68(2):449-461. View in PubMed
  113. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 05; 102(5):816-822. View in PubMed
  114. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1. View in PubMed
  115. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018 04; 102(4):640-647. View in PubMed
  116. B. Lee, G. Im, J. Dodge, M. Voigt, J. Rice, M.R. Lucey, D. Foley, L. Platt, A. Gurakar, N. Mehta, G. Therapondos, H. Han, D. Victor, O. Fix, L. Dinges, D. Dronamraju, C. Hsu, M. Rinella, H. Maddur, S. Eswaran, J. Hause, R.M. Ghobrial, Z. Li, N. Terrault. SAT-448 Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis. . 2018 Apr 1; 68:s808. View in PubMed
  117. E. Phillips, R. Kohlbrenner, A. True-Yasaki, N. Fidelman, A. Taylor, E. Lehrman, M. Kohi, K. Kolli, R. Kerlan, N. Mehta. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection. . 2018 Apr 1; 29(4):s220. View in PubMed
  118. M. Kohi, M. Sarka, J. Dodge, J. Roberts, N. Terrault, N. Mehta. Abstract No. 525 Liver transplantation rates for hepatocellular carcinoma: is there a sex-related difference?. . 2018 Apr 1; 29(4):s221. View in PubMed
  119. E. Phillips, R. Kohlbrenner, A. True-Yasaki, N. Fidelman, A. Taylor, E. Lehrman, M. Kohi, K. Kolli, R. Kerlan, N. Mehta. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection. Journal of Vascular and Interventional Radiology. 2018 Apr 1; 29(4):s220. View in PubMed
  120. M. Kohi, M. Sarka, J. Dodge, J. Roberts, N. Terrault, N. Mehta. Abstract No. 525 Liver transplantation rates for hepatocellular carcinoma: is there a sex-related difference?. Journal of Vascular and Interventional Radiology. 2018 Apr 1; 29(4):s221. View in PubMed
  121. B. Lee, G. Im, J. Dodge, M. Voigt, J. Rice, M.R. Lucey, D. Foley, L. Platt, A. Gurakar, N. Mehta, G. Therapondos, H. Han, D. Victor, O. Fix, L. Dinges, D. Dronamraju, C. Hsu, M. Rinella, H. Maddur, S. Eswaran, J. Hause, R.M. Ghobrial, Z. Li, N. Terrault. SAT-448 Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis. Journal of Hepatology. 2018 Apr 1; 68:s808. View in PubMed
  122. Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 03; 24(3):327-329. View in PubMed
  123. Azeem N, Ajmera V, Hameed B, Mehta N. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels. Hepatol Commun. 2018 04; 2(4):349-353. View in PubMed
  124. Mehta NJ, Latoures R, Stechert MM, Fidler RL, Hirsch J. Interventions to improve the mechanical ventilation fidelity of the Laerdal SimMan® 3G simulation mannequin. Can J Anaesth. 2018 05; 65(5):600-602. View in PubMed
  125. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018 05; 18(5):1206-1213. View in PubMed
  126. Mehta N, Yao FY. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl. 2017 12; 23(12):1596-1600. View in PubMed
  127. Elizabeth Phillips, Ryan Kohlbrenner, Aisha True-Yasaki, Nicholas Fidelman, Neil Mehta. Outcomes of TACE in HIV-Positive Patients with Hepatocellular Carcinoma. . 2017 Dec 1; 01. View in PubMed
  128. Elizabeth Phillips, Ryan Kohlbrenner, Aisha True-Yasaki, Nicholas Fidelman, Neil Mehta. Outcomes of TACE in HIV-Positive Patients with Hepatocellular Carcinoma. Digestive Disease Interventions. 2017 Dec 1; 01. View in PubMed
  129. Mehta N, Elo I, Stenholm S, Aromaa A, Heliövaara M, Koskinen S. International Differences in the Risk of Death from Smoking and Obesity: The Case of the United States and Finland. SSM Popul Health. 2017 Dec; 3:141-152. View in PubMed
  130. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018 06; 16(6):955-964. View in PubMed
  131. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant. 2017 Nov; 31(11). View in PubMed
  132. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 09; 101(9):2071-2078. View in PubMed
  133. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. View in PubMed
  134. Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368. View in PubMed
  135. Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation. 2017 05; 101(5):1001-1008. View in PubMed
  136. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500. View in PubMed
  137. Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun. 2017 02; 1(1):18-22. View in PubMed
  138. Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 12; 151(6):1062-1065. View in PubMed
  139. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 10; 64(4):1178-88. View in PubMed
  140. Mehta N, Yao FY. Reply. Liver Transpl. 2016 08; 22(8):1164-5. View in PubMed
  141. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9. View in PubMed
  142. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul - Aug; 15(4):545-549. View in PubMed
  143. Mehta N, Roberts JP, Yao FY. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4. View in PubMed
  144. Lê-Scherban F, Albrecht SS, Bertoni A, Kandula N, Mehta N, Diez Roux AV. Immigrant status and cardiovascular risk over time: results from the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2016 06; 26(6):429-435.e1. View in PubMed
  145. Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Curr Opin Organ Transplant. 2016 Apr; 21(2):91-8. View in PubMed
  146. G. Sapisochin, N. Mehta, I. Scalera, C. Sposito, F.Y. Yao, P. Muiesan, V. Mazzaferro, D.R. Grant. HCC recurrence following liver tranplantation should be aggresively treated to increase patient survival. . 2016 Apr 1; 18:e197. View in PubMed
  147. G. Sapisochin, M. Facciuto, N. Mehta, E. Vibert, R. Hernandez-Alejandro, A.D. Pinna, S. Hwang, V.G. Agopian, G. Gores, J. Reyes, O. Soubrane, T. Reichman, P. Kim, C. Sposito, P.A. Clavien, C. Toso, N. Kneteman, J. Bruix. “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study. . 2016 Apr 1; 18:e46-e47. View in PubMed
  148. G. Sapisochin, N. Mehta, I. Scalera, C. Sposito, F.Y. Yao, P. Muiesan, V. Mazzaferro, D.R. Grant. HCC recurrence following liver tranplantation should be aggresively treated to increase patient survival. Hepato Pancreato Biliary. 2016 Apr 1; 18:e197. View in PubMed
  149. G. Sapisochin, M. Facciuto, N. Mehta, E. Vibert, R. Hernandez-Alejandro, A.D. Pinna, S. Hwang, V.G. Agopian, G. Gores, J. Reyes, O. Soubrane, T. Reichman, P. Kim, C. Sposito, P.A. Clavien, C. Toso, N. Kneteman, J. Bruix. “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study. Hepato Pancreato Biliary. 2016 Apr 1; 18:e46-e47. View in PubMed
  150. Mehta N, Yao FY. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology. 2016 May; 63(5):1415-7. View in PubMed
  151. Mehta N, Preston S. Are major behavioral and sociodemographic risk factors for mortality additive or multiplicative in their effects? Soc Sci Med. 2016 Apr; 154:93-9. View in PubMed
  152. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016 Feb; 22(2):178-87. View in PubMed
  153. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4. View in PubMed
  154. Gabriel Brooks, Kathryn Brown, Neil Mehta, Karen Ordovas, Nevah Rubin, Elyse Foster, Atif Qasim. Abstract 19009: The Association Between Clinical and Echocardiographic Imaging Findings and T2* in End Stage Liver Disease. Circulation. 2015 Nov 10; 132(suppl_3). View in PubMed
  155. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77. View in PubMed
  156. Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant. 2015 Jan; 29(1):52-9. View in PubMed
  157. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8. View in PubMed
  158. Yao FY, Hameed B, Mehta N, Roberts JP. Response to letter to the editors. Liver Transpl. 2014 Oct; 20(10):1285. View in PubMed
  159. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014 Aug; 20(8):945-51. View in PubMed
  160. M. Samoylova, J. Dodge, F. Yao, N. Mehta, J. Roberts. Should Hepatocellular Carcinoma Patients With Multiple Tumors <2cm Be Transplanted?. . 2014 Jul 1; 98:698. View in PubMed
  161. M. Samoylova, J. Dodge, F. Yao, N. Mehta, J. Roberts. Should Hepatocellular Carcinoma Patients With Multiple Tumors <2cm Be Transplanted?. Transplantation Journal. 2014 Jul 1; 98:698. View in PubMed
  162. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8. View in PubMed
  163. Srinivasan M, Mehta N. BMJ endgames: a new web-based BMJ/JGIM collaboration. J Gen Intern Med. 2014 Mar; 29(3):423-4. View in PubMed
  164. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013 Dec; 19(12):1343-53. View in PubMed
  165. Mendelsohn BA, Mehta N, Hameed B, Pekmezci M, Packman S, Ralph J. Adult-Onset Fatal Neurohepatopathy in a Woman Caused by MPV17 Mutation. JIMD Rep. 2014; 13:37-41. View in PubMed
  166. Mehta N, Yao FY. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013 Oct; 19(10):1055-8. View in PubMed
  167. Yao F, Mehta N. Reply: To PMID 23333661. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1674. View in PubMed
  168. Mehta N, Hirose R. Immunosuppression: Conventions and controversies. Clin Liver Dis (Hoboken). 2013 Aug; 2(4):188-191. View in PubMed
  169. Turney K, Lee H, Mehta N. The social determinants of child health. Soc Sci Med. 2013 Oct; 95:1-5. View in PubMed
  170. Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013 May; 11(5):572-8. View in PubMed
  171. Neil Mehta, Aparna Goel, Karen C. Bagatelos, James L. Buxbaum, Nicholas Fidelman, John P. Roberts, Norah A. Terrault, Francis Yao, James W. Ostroff. 1016 Risk of Hepatic Artery and Biliary Complications in Liver Transplant Recipients Treated With Transarterial Chemoembolization. . 2012 May 1; 142(5):s-939-s-940. View in PubMed
  172. Neil Mehta, Aparna Goel, Karen C. Bagatelos, James L. Buxbaum, Nicholas Fidelman, John P. Roberts, Norah A. Terrault, Francis Yao, James W. Ostroff. 1016 Risk of Hepatic Artery and Biliary Complications in Liver Transplant Recipients Treated With Transarterial Chemoembolization. Gastroenterology. 2012 May 1; 142(5):s-939-s-940. View in PubMed
  173. Miller J, Mehta N, Feldman M, Furth E, Ginsberg GG, Yang YX, Lewis JD. Findings on serial surveillance colonoscopy in patients with low-risk polyps on initial colonoscopy. J Clin Gastroenterol. 2010 Mar; 44(3):e46-50. View in PubMed
  174. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83. View in PubMed